回顾了缓释芬特明/托吡酯的代谢影响。

文章的细节

引用

复制到剪贴板

医学会主席DN奇奥尔特西斯

回顾了缓释芬特明/托吡酯的代谢影响。

激素(雅典)。Oct-Dec 2013; 12 (4): 507 - 16。

PubMed ID

24457398 (在PubMed

]

文摘

背景和目的:很少有药物是由监管机构批准用于肥胖症的治疗。最近芬特明/托吡酯缓释(苯酚的/ TPM铬;(Qsymia (R)))获得食品和药物管理局(FDA)批准的除了热量饮食和锻炼慢性体重管理。我们的目的是审查现有的临床证据减肥,代谢影响和不良事件与使用这种产品。方法:随机对照试验与苯丁胺/托吡酯缓释选择通过Medline搜索使用条款:芬特明和托吡酯,苯丁胺和控制释放托吡酯,最近新的抗肥胖药物和芬特明/托吡酯治疗肥胖的药物组合和(R)。必威国际app结果:苯酚的/ TPM CR与减肥有关的8.1 - -10.9%(分别为中、高剂量),而安慰剂组患者失去了他们最初的重量的1.4 - -1.8%。苯酚的/ TPM CR也导致腰围的显著下降。减肥与苯酚的/ TPM CR与血压下降但略有增加的心率。此外,在所有试验对血脂产生有利的影响,尤其是甘油三酯和高密度lipopoprotein(高密度脂蛋白)胆固醇。苯酚的/ TPM CR治疗也改善胰岛素敏感性和血糖。 Moreover, it decreased significantly progression to type 2 diabetes. In all of the studies the severe adverse events were similar between the control groups and the groups of PHEN/TPM CR. The most frequent side-effects observed in the active treatment group were paresthesia, dysgeusia, dry mouth, constipation and insomnia. WHAT IS NEW AND CONCLUSION: PHEN/TPM CR combined with lifestyle modification may be an effective and well-tolerated treatment for obesity and weight-related metabolic complications. Its long-term efficacy and safety have yet to be defined.

DrugBank数据引用了这篇文章

药物

芬特明